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Abstract
Background—Despite clear guidelines for its use and wide adoption, no population-based study 
has examined the extent to which patients with early stage breast cancer are benefiting from 
sentinel lymph node biopsy (SLNB) by being spared a potentially avoidable axillary lymph node 
dissection (ALND) and its associated morbidity.
Objective—Examine variation in type of axillary surgery performed by surgeon volume; 
investigate the extent and consequences of potentially avoidable ALND.
Research design/subjects—Observational study of older women with pathologically node-
negative Stage I–II invasive breast cancer who underwent surgery in a SEER state in 2008–2009.
Measures—Surgeon annual volume of breast cancer cases and type of axillary surgery were 
determined by Medicare claims. An estimated probability of excess lymphedema due to ALND 
was calculated.
Results—Among 7,686 pathologically node-negative women, 49% underwent ALND (either 
initially or after SLNB) and 25% were operated on by low volume surgeons. Even after adjusting 
for demographic and tumor characteristics, women treated by higher volume surgeons were less 
likely to undergo ALND (medium volume: OR 0.69 [95% CI 0.51–0.82]; high volume: OR 0.59 
[95% CI 0.45 – 0.76]). Potentially avoidable ALND cases were estimated to represent 21% of all 
expected lymphedema cases.
Conclusions—In this pathologically node-negative population-based breast cancer cohort, only 
half underwent solely SLNB. Patients treated by low volume surgeons were more likely to 
undergo ALND. Resources and guidelines on the appropriate training and competency of surgeons 
to assure the optimal performance of SLNB should be considered to decrease rates of potentially 
avoidable ALND and lymphedema.
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INTRODUCTION
Sentinel lymph node biopsy (SLNB) is the standard of care for axillary staging in early 
stage, clinically node-negative breast cancer.1–3 Randomized controlled trials have 
demonstrated that patients undergoing SLNB, compared to axillary lymph node dissection 
(ALND), have similar disease-free survival but lower incidence of lymphedema and other 
arm/shoulder morbidity which are associated with decreased quality of life and increased 
costs.4–10 One recommendation on the American College of Surgeons Choosing Wisely® 
list is to not perform ALND on patients with clinically node-negative stage I–II breast 
cancer without attempting SLNB.11
Despite these findings and recommendations supporting the use of SLNB, it remains unclear 
whether this major advance is improving the outcomes of the large majority of women with 
early stage breast cancer who are treated in the community by surgeons who perform 
relatively few breast cancer operations.12,13 Importantly, there is a learning curve to 
accurately perform SLNB.14–18 Proponents, including the American Society of Breast 
Surgeons, advocated in the earlier years of SLNB that surgeons needed to perform 20–30 
SLNBs with completion ALND to achieve high accuracy rates.16,19,20 Recent studies have 
demonstrated that women are more likely to undergo SLNB if they are treated by surgeons 
who specialize or focus in breast cancer, defined by volume or percentage of breast cancer 
cases and membership in breast and surgical oncology societies.21–23
In the SLNB era, reasons why a woman may undergo ALND include: preoperative evidence 
of lymph node involvement; preoperative clinical, radiographic and/or intraoperative 
concern for metastasis; SLNB reveals metastasis; attempted but failed SLNB; SLNB not 
offered by surgeon; SLNB not available at treating facility. Surgeons with less experience 
and expertise with SLNB may be less likely to offer SLNB, more likely to not identify 
sentinel nodes, and more likely to perform ALND after a negative SLNB if there is 
intraoperative concern whether the sentinel node was accurately identified and/or if any 
axillary (sentinel and/or non-sentinel) nodes are grossly concerning for metastasis.
Although the efficacy of SLNB has been established in clinical trials and SLNB was adopted 
into clinical practice by the mid-2000s,24,25 no population-based effectiveness study has 
determined the extent to which early stage breast cancer patients are benefiting from SLNB 
by being spared a potentially avoidable ALND, thereby avoiding a higher risk of 
lymphedema. This study, performed in a pathologically node-negative population-based 
cohort, addresses this gap in knowledge by examining variation in type of axillary surgery 
by surgeon volume, and investigating the prevalence and consequences of ALNDs with a 
special focus on excess lymphedema.
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METHODS
Study Cohort and Data Sources
Data are from the National Cancer Institute’s Surveillance, Epidemiology, and End Results 
(SEER)-Medicare linked data set.26 The cohort consisted of women 66–90 years of age at 
the time of diagnosis of an initial incident, unilateral, pathologic T1/T2N0M0 invasive 
ductal, lobular or mixed ductal/lobular breast cancer from January 1, 2008 through 
December 31, 2009 who underwent breast and axillary surgery in a SEER state and had at 
least one lymph node removed. We focus on pathologically node-negative women as these 
are the cases that could have potentially avoided an ALND as none had any positive axillary 
lymph nodes (sentinel or non-sentinel) removed. Women had to be enrolled in Medicare 
Parts A and B for at least 12 months before and 12 months after the breast cancer diagnosis 
(or until death if died less than 12 months after diagnosis). Women were excluded if they 
were enrolled in a health maintenance organization (because of incomplete claims 
information), had locally advanced or inflammatory tumors (pT3/T4N0M0), had an 
unknown number of lymph nodes removed (n=56) and/or underwent neoadjuvant 
chemotherapy as a complete pathologic response after neoadjuvant chemotherapy might be 
incorrectly classified as a potentially avoidable ALND.
Lastly, cases had to have an identifiable surgeon by claims who only operated in one of the 
10 state-wide SEER registries and performed at least one breast surgery. Surgeons who 
performed cases in non-SEER states and those that operated in the Detroit and Seattle-Puget 
Sound SEER registries, and their respective patients, were excluded to avoid potential 
misrepresentation of surgeon volume because operations performed outside of SEER states 
and non-SEER regions in Michigan and Washington states were not captured.
Outcome Variables
Type of axillary surgery performed was not available through SEER.27 As a result, after 
reviewing the existing literature, our own prior work, and coding manuals, the type of 
axillary surgery (SLNB only, SLNB followed by ALND, ALND only) was defined based on 
Medicare claims.23,28–34 ALND was defined as the presence of any one of 18 
lymphadenectomy codes (Current Procedural Terminology [CPT] 19162, 19200, 19220, 
19240, 19302, 19305, 19306, 19307, 38740, 38745; International Classification of Disease, 
9th revision [ICD-9] 40.3, 40.5, 40.51, 85.43, 85.45–85.48). SLNB was defined as the 
presence of at least one of 8 codes related to radioactive dye (Healthcare Common 
Procedure Coding System [HCPCS] A9520, A9541); injection for lymphangiography (CPT 
38790, 38792); lymphatic/lymph node imaging (CPT 78195); or axillary lymph node 
excisional biopsy (CPT 38500, 38525, ICD-9 40.23). Patients who had claims on the same 
or different days for both SLNB and ALND were classified as starting with SLNB and 
converting to ALND. A potentially avoidable ALND was defined as either an initial ALND 
or initial SLNB that converted to ALND because there would not have been any indication 
for ALND based on pathologically node-negative status.
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Other Variables
Patient age and race were determined from Medicare files. Comorbidity was determined 
from the inpatient, outpatient and carrier Medicare data for the year preceding the incident 
breast cancer diagnosis using Klabunde’s algorithm.35 Tumor characteristics (size, grade, 
lymph node status, number of lymph nodes removed, number of positive lymph nodes, 
tumor stage) were determined from the SEER registry. Treatment variables were defined by 
Medicare claims and included type of definitive/final breast surgery and receipt of radiation 
therapy, chemotherapy and hormonal therapy within 12 months of definitive breast surgery.
Surgeon volume was determined from all SEER state-Medicare breast cancer cases who met 
the above inclusion criteria, regardless of stage and receipt of neoadjuvant chemotherapy. 
Based on this larger cohort of about 23,000 cases, the annual number of breast cancer cases 
was calculated for each surgeon for each year and averaged over the two-year period. After 
examining the distribution of surgeon case volume, surgeons were classified into one of 
three groups (low, medium and high) each year, with roughly one-third of cases at the 
patient level in each volume group. Low volume surgeons were defined as those performing 
5 or fewer SEER-Medicare breast cancer cases annually, which corresponds to about <13 
breast cancer cases of all ages annually. High volume surgeons were defined as performing 
more than 15 cases annually (corresponding to about >37 cases of all ages annually), 
representing at least a tripling of cases compared to the low volume cut-off. These cut-offs 
are similar to thresholds used in prior breast cancer studies.36–38
Statistical Analysis
To predict the likelihood of undergoing an ALND by surgeon volume, a logistic regression 
model at the patient level with physician-specific random effects was estimated. The model 
included surgeon volume plus several categorical covariates (age, race, comorbidity, SEER 
state, tumor size, grade and hormone receptor status) that could affect the type of axillary 
surgery performed. Missing tumor variable information was treated as a separate category. 
Estimates were calculated using the GLIMMIX procedure in SAS statistical software 
(Version 9.3, SAS Institute; Cary, NC).
Estimated probabilities of lymphedema were determined empirically from a comparable 
Medicare cohort (pathologically node-negative and had at least one lymph node removed) 
that was prospectively followed for the development of lymphedema;39 the 5-year actual 
rates of lymphedema were 9.5%, 22.5%, 34.5% and 40.6% when 1–5, 6–10, 11–15, and 16 
or more lymph nodes were removed, respectively. For this study, since actual rates of 
lymphedema are not known, we assigned each patient a 5-year estimated probability of 
lymphedema based on the number of lymph nodes removed in SEER and above rates of 
lymphedema. For each of the three axillary surgery groups and total cohort, the number of 
estimated lymphedema patients was determined. For the SLNB to ALND conversion group, 
ALND only group and total cohort, the excess lymphedema probability (lymphedema 
probability minus lymphedema probability of SLNB group), and number of estimated 
excess lymphedema patients were calculated.
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RESULTS
The study cohort consists of 7,686 women with pathologically node-negative Stage I–II 
invasive breast cancer who underwent incident breast cancer surgery between January 1, 
2008 and December 31, 2009. Table 1 summarizes the patient and tumor characteristics of 
the cohort. The mean age at cancer diagnosis was 74.9 years (SD 6.1); most were white and 
over half had no comorbidities. The majority had tumors that were hormone receptor-
positive (83%) and Stage I (80%). Two-thirds underwent breast-conserving surgery, 60% 
received radiation, 13% underwent chemotherapy and two-thirds received hormonal therapy.
Overall, 1,759 surgeons treated the study cohort. The overall mean annual number of SEER 
state-Medicare breast cancer cases per surgeon was 6.0 (SD 7.0; range 0.25 – 74). The 
majority (63%) of surgeons were classified as low volume; 28% were medium volume and 
8% were high volume. Mean annual volume of SEER-Medicare breast cancer cases was 1.9 
(SD 1.2), 5.9 (SD 3.0) and 17.9 (SD 8.4) for low, medium and high volume surgeons, 
respectively.
Surgeon volume and ALND
Among the 7,686 women with pathologically node-negative breast cancer, 51% (n=3,889) 
underwent SLNB only and 49% (n=3,797) underwent a potentially avoidable ALND (Table 
1). Among those undergoing ALND, 79% (n=3,015) initially started with SLNB and 
converted to ALND while the remaining 782 underwent only ALND. Compared to those 
undergoing SLNB only, women who underwent an ALND were slightly older, had more 
comorbidities, and had tumors that were larger, high grade, Stage II and less likely to be 
hormone receptor-positive.
Overall, 25%, 42% and 33% of women were treated by low, medium and high volume 
surgeons, respectively. In unadjusted analyses, women undergoing ALND were less likely to 
be operated on by higher volume surgeons. Table 2 displays the results of the multiple 
logistic regression model with physician-specific random effects, controlling for possible 
confounders. Women with larger tumors and those with unknown hormone receptor status 
were more likely to undergo ALND. Compared to patients operated on by low volume 
surgeons, those operated on by high and medium volume surgeons were less likely to 
undergo ALND.
Excess lymphedema rates
The mean number of nodes removed in the SLNB only, SLNB converted to ALND and 
ALND only groups was 2.8 (SD 2.5), 4.4 (SD 4.5) and 11.7 (SD 6.8), respectively (Table 3). 
The estimated 5-year lymphedema probability rates were 11.0%, 14.1% and 28.2% for 
women undergoing SLNB only, SLNB converted to ALND, and ALND only, respectively, 
resulting in an overall 5-year lymphedema probability rate of 13.9% (1,068 patients) for the 
entire cohort. We considered the baseline probability of lymphedema as 11.0%, as it 
corresponds to the probability of lymphedema among women undergoing SLNB only in this 
study cohort. Therefore, estimated excess lymphedema probabilities were 3.1% (93 patients) 
and 17.2% (135 patients) in the conversion group and ALND only group, respectively. For 
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the entire cohort, the number of estimated lymphedema cases was 1,068. If we assume that 
all patients were legitimate candidates to undergo SLNB only, we would expect 845 cases of 
lymphedema (7,686 × 0.11). Under this assumption, we estimate an excess of 223 cases of 
lymphedema, which accounts for 21% (223/1068) of all expected lymphedema cases. Since 
SEER registries cover about 28% of the US population, we conservatively estimate 
approximately 3,814 (1,068/0.28) potential cases of lymphedema of which approximately 
796 (223/0.28) lymphedema cases in a nationwide Medicare cohort would have been 
potentially avoidable.
DISCUSSION
In this contemporary, population-based cohort of nearly 7,700 women with stage I–II 
pathologically node-negative breast cancer, the vast majority (89%) underwent an initial 
SLNB. However, since 44% converted to ALND and 10% underwent initial ALND, 
ultimately 51% underwent SLNB only and 49% underwent an ALND. Compared to low 
volume surgeons, patients treated by higher volume surgeons were significantly less likely to 
undergo an ALND. We estimate that these potentially avoidable ALND cases represent 21% 
of all expected lymphedema cases.
Although guidelines from the National Comprehensive Cancer Network and American 
Society of Clinical Oncology included SLNB as an alternative to ALND for early stage 
breast cancer as early as the late 1990s and early 2000s and prior studies report on the 
adoption of SLNB by the mid-2000s,24,25,40,41 our findings suggest only partial adoption of 
performing only SLNB in the community by even the late 2000s. As a result, half of these 
pathologically node-negative patients are undergoing potentially avoidable ALNDs and 
therefore subjected to an avoidable excess risk of lymphedema. These findings are 
particularly relevant as the indications to perform only SLNB, and not proceed to 
completion ALND, particularly in the setting of minimal axillary disease, will likely 
continue to expand.1,42 The observed overuse of ALND in elderly women is especially 
troublesome since national guidelines2 consider axillary staging (SLNB or ALND) as 
optional in patients who have particularly favorable tumors, those for whom selection of 
adjuvant systemic treatment will not be affected by the results, and those with serious 
comorbid conditions, criteria that are commonly present in elderly women.
To our knowledge, this is the first population-based study of pathologically node-negative 
patients to examine rates of ALND and to report these patients are less likely to undergo 
ALND (either initially or after SLNB) if cared for by a surgeon with a higher volume of 
breast cancer cases. Our findings add to the growing body of literature that demonstrate 
women with breast cancer are more likely to undergo SLNB if they are cared for by 
surgeons who specialize in breast cancer care, defined as performing higher volume or 
percentage of breast cancer cases or holding membership in breast and surgical oncology 
societies.21–23 Hospitals, particularly lower volume hospitals, should carefully consider 
these qualifications when hiring surgeons to ensure high quality breast cancer surgical care.
Our definition of SLNB, similar to prior studies,31–34 was based on procedural claims 
related to lymphangiography, lymphatic/lymph node mapping or axillary lymph node 
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excisional biopsy because the type of axillary surgery performed was not available in 
SEER27 and this cohort underwent surgery prior to 2011, when a CPT code specific to the 
performance of SLNB (38900) became available. Although Medicare billing claims are 
generally accurate for breast cancer surgical billing codes,32,43,44 it is possible that 
misclassification of the type of axillary surgery performed occurred. In particular, since 39% 
of patients had claims for both SLNB and ALND and since this SLNB to ALND conversion 
group had fewer nodes removed than the ALND only group, it is possible that this 
conversion group is contaminated with some patients who underwent only SLNB. However, 
if the number of nodes removed is correctly reported in SEER, our reported rates of excess 
lymphedema are accurate and represent the most conservative estimates. To address the 
issue of possible contamination, a sensitivity analysis was performed among the SLNB to 
ALND conversion group where patients were apportioned to either SLNB or ALND based 
on the conditional probability of undergoing either axillary surgery given the number of 
nodes removed. The risk of lymphedema in the conversion group was estimated to be 16.5% 
after reapportioning patients to SLNB or ALND. If the conversion group were contaminated 
with patients who only underwent SLNB, we would expect to find a lower (not higher) rate 
of lymphedema in this sensitivity analysis, compared to our reported finding of 14.1%. 
Another possibility for the relatively low number of nodes removed in the conversion group 
(compared to the ALND only group) is that this conversion group underwent random 
“axillary sampling” in addition to SLNB, although there is no data to support such an 
approach.
A limitation of this study is that the SEER registry does not provide clinical stage 
information for cases that have pathological stage information; therefore, we could not 
restrict our study to a clinically and pathologically node-negative cohort. We would argue, 
however, that a pathologically node-negative cohort is the most appropriate from the patient 
perspective, as those who underwent an ALND (albeit retrospectively) were subjected to a 
potentially avoidable, invasive procedure with significant morbidity. It is important to note 
that, within the National Cancer Database (NCDB), a hospital-based cancer outcomes 
database of more than 1,500 Commission on Cancer-accredited cancer programs, 76% of 
pathologically node-negative patients treated in 2013–2014 underwent SLNB only. Adding 
the requirement of being clinically node-negative to this pathologically node-negative cohort 
yields an unchanged proportion of women undergoing SLNB only (77%). Equally as 
important, only 8% of clinically node-positive patients were pathologically node-negative. In 
addition, a recent abstract reported only a 0.5% likelihood of nodal downstaging (clinically 
node-positive to pathologically node-negative) in women with Stage 1–3 hormone receptor-
positive breast cancer.45 Therefore, our inability to identify clinically node-negative cases is 
not likely to alter our results appreciably. To our knowledge, no database includes clinical 
and pathologic stage and provider information. While the NCDB includes clinical and 
pathologic stage, it does not include information on surgeon characteristics, preventing the 
replication of this study in NCDB.
Inherent to claims-based, retrospective studies is our inability to determine the factors and 
reasons (patient, tumor, surgeon, hospital) for starting with or converting to ALND in 
pathologically node-negative patients. Therefore, we cannot ascertain the “appropriateness” 
of 49% of the cohort undergoing ALND. Our purpose was to examine the type of axillary 
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surgery performed; we make no value judgements regarding the appropriateness of that 
decision-making. For patients who underwent initial ALND, we do not know whether these 
cases involved surgeons who did not offer SLNB because of preoperative clinical or 
radiographic concerns for axillary lymph node metastasis, do not perform SLNB, or are at a 
facility where the resources to perform SLNB are not available. For patients who converted 
to ALND after SLNB, we do not know whether this was because a sentinel node was not 
identified or, if identified, whether the surgeon was confident that the sentinel node(s) was/
were accurately identified, or if there was intraoperative concern for axillary (sentinel or 
non-sentinel) metastasis. We cannot determine what proportion of patients underwent a 
preoperative axillary ultrasound or had intraoperative frozen section of any lymph nodes 
(sentinel or non-sentinel) performed. Lastly, since this study was confined to Medicare 
patients, our findings may not be generalizable to younger populations.
In conclusion, this study provides important clinical and policy relevant findings regarding 
the translation of the efficacy of SLNB established in clinical trials to community-based, 
population-wide effectiveness. First, given the higher likelihood of pathologically node-
negative women undergoing ALND by low volume surgeons, patients and referring 
providers should be cognizant of their surgeons’ experience with breast cancer cases and 
SLNB. Second, since half of pathologically node-negative patients underwent an ALND, 
optimization of both preoperative nodal assessment (e.g., axillary ultrasound, preoperative 
biopsy for clinically node-positive patients) and intraoperative management of lymph nodes 
(e.g., frozen section of suspicious nodes, particularly if a negative result would preclude 
immediate ALND) to appropriately select patients for potentially SLNB only surgery is 
necessary. Furthermore, references (e.g. Operative Standards for Cancer Surgery46 by the 
American College of Surgeons Clinical Research Program and the Alliance for Clinical 
Trials in Oncology; a troubleshooting guide for SLNB47) and policies on appropriate 
surgeon training and competency in SLNB (e.g. training programs, societal proficiency 
guidelines and consensus statements) should be considered to assure the optimal 
performance of SLNB in the community. Lastly, since post-treatment lymphedema is 
associated with significantly decreased quality of life and increased costs4–10 and we 
estimate that almost a quarter of all expected lymphedema cases are due to potentially 
avoidable ALNDs, regionalization of initial surgical care to centers with the necessary 
experience and resources to perform SLNB may need to be considered to decrease rates of 
ALND and ultimately lymphedema and other arm morbidity among breast cancer survivors.
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Table 1
Patient, tumor and surgeon characteristics, by type of axillary surgery, among 7,686 pathologically node-
negative women
Total cohort
N=7,686
SLNB only
N=3,889 (51%)
ALND*
N=3,797 (49%) p-value
Patient characteristics
Age (years) 0.003†
 66 – 69 1,774 (23%) 940 (24%) 834 (22%)
 70 – 74 2,167 (28%) 1,124 (29%) 1,043 (28%)
 75 – 79 1,857 (24%) 932 (24%) 925 (24%)
 80+ 1,888 (25%) 893 (23%) 995 (26%)
Mean (SD) 74.9 (6.1) 74.7 (6.0) 75.2 (6.2)
Race 0.16
 White 6,798 (88%) 3,466 (89%) 3,332 (88%)
 Black 496 (6%) 233 (6%) 263 (7%)
 Other 392 (5%) 190 (5%) 202 (5%)
Comorbidity 0.001
 0 4,106 (53%) 2,156 (55%) 1,950 (51%)
 1 2,136 (28%) 1,044 (27%) 1,092 (29%)
 2+ 1,444 (19%) 689 (18%) 755 (20%)
Extent of disease
Tumor size (cm)
 0 – 2 6,015 (78%) 3,161 (81%) 2,854 (75%) <0.001†
 > 2 – 5 1,560 (20%) 665 (17%) 895 (24%)
 Unknown 111 (1%) 63 (2%) 48 (1%)
Mean (SD) 1.5 (0.9) 1.4 (0.8) 1.6 (0.9)
Tumor grade <0.001
 Low 2,125 (28%) 1,136 (29%) 989 (26%)
 Moderate 3,548 (46%) 1,805 (46%) 1,743 (46%)
 High 1,754 (23%) 828 (21%) 926 (24%)
 Unknown 259 (3%) 120 (3%) 139 (4%)
Hormone receptor status <0.001
 Positive 6,371 (83%) 3,290 (85%) 3,081 (81%)
 Negative 1,012 (13%) 478 (12%) 534 (14%)
 Unknown 303 (4%) 121 (3%) 182 (5%)
AJCC tumor stage <0.001
 I 6,126 (80%) 3,224 (83%) 2,902 (76%)
 II 1,560 (20%) 665 (17%) 895 (24%)
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Total cohort
N=7,686
SLNB only
N=3,889 (51%)
ALND*
N=3,797 (49%) p-value
Number of lymph nodes removed <0.001†
 1 – 5 5,961 (78%) 3,535 (91%) 2,426 (64%)
 6 – 10 928 (12%) 280 (7%) 648 (17%)
 11 – 15 463 (6%) 56 (1%) 407 (11%)
 16+ 334 (4%) 18 (0.5%) 316 (8%)
Mean (SD) 4.3 (4.7) 2.8 (2.5) 5.9 (5.8)
Surgeon factor
Surgeon volume
 Low 1,882 (25%) 808 (21%) 1,074 (28%) <0.001
 Medium 3,234 (42%) 1,704 (44%) 1,530 (40%)
 High 2,570 (33%) 1,377 (35%) 1,193 (31%)
Abbreviations: AJCC, American Joint Committee on Cancer; SD, standard deviation
*ALND defined as patients who either underwent initial SLNB and converted to ALND (n=3,015) or underwent ALND only (n=782).
†
For continuous variable comparison, p<0.001
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Table 2
Logistic regression model with physician-specific random effects predicting the likelihood of pathologically 
node-negative women undergoing ALND
Characteristics Odds Ratio 95% CI p-value
Surgeon volume <0.001
 Low 1.00
 Medium 0.69 0.51 – 0.82
 High 0.59 0.45 – 0.76
Patient characteristics
Age (years) 0.26
 66 – 69 1.00
 70 – 74 1.04 0.89 – 1.20
 75 – 79 1.11 0.94 – 1.30
 80+ 1.16 0.99 – 1.36
Race 0.30
 White 1.00
 Black 1.00 0.80 – 1.27
 Other 1.24 0.94 – 1.64
Comorbidity 0.81
 0 1.00
 1 1.04 0.91 – 1.18
 2+ 1.04 0.89 – 1.20
Tumor factors
Tumor size <0.001
 0 – 2 1.00
 > 2 – 5 1.49 1.29 – 1.71
 Missing 0.86 0.54 – 1.38
Tumor grade 0.66
 Low 1.00
 Medium 1.05 0.92 – 1.20
 High 1.11 0.94 – 1.32
 Missing 1.10 0.79 – 1.52
Hormone receptor status 0.005
 Positive 1.00
 Negative 1.12 0.94 – 1.34
 Unknown 1.60 1.19 – 2.15
Adjusted for SEER state
Abbreviations: ALND, axillary lymph node dissection; CI, confidence interval
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Table 3
Number of nodes removed and estimates of lymphedema and excess lymphedema by type of axillary surgery 
performed
SLNB only
N=3,889 (51%)
SLNB to ALND
N=3,015 (39%)
ALND only
N=782 (10%)
Overall cohort
N=7,686
No. nodes removed
 Mean (SD) 2.8 (2.5) 4.4 (4.5) 11.7 (6.8) 4.3 (4.7)
 Median (Q1–Q3) 2 (1–3) 3 (2–5) 11 (7–16) 3 (1–5)
Lymph node category (n;%)
 1–5 3,535 (91%) 2,276 (76%) 150 (19%) 5,961 (78%)
 6–10 280 (7%) 441 (15%) 207 (26%) 928 (12%)
 11–15 56 (1.4%) 196 (6%) 211 (27%) 463 (6%)
 16+ 18 (0.5%) 102 (3%) 214 (27%) 334 (4%)
5-year estimated lymphedema probability 11.0% 14.1% 28.2% 13.9%
Estimated excess lymphedema probability* 0 3.1% 17.2% 2.9%
No. of estimated lymphedema patients† 428 425 221 1,068
No. of estimated excess lymphedema pts‡ 0 93 135 223
Abbreviations: ALND, axillary lymph node dissection; No., number; Q, quartile; SD, standard deviation; SLNB, sentinel lymph node biopsy
*
Estimated excess lymphedema probability = lymphedema probability minus the baseline 11.0% estimated lymphedema probability of SLNB only 
group
†Number of estimated lymphedema patients = total number of patients × estimated lymphedema probability
‡Number of estimated excess lymphedema patients = total number of patients × estimated excess lymphedema probability
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